{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:44:42Z","timestamp":1787589882334,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ahj.2025.107283","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:42:00Z","timestamp":1759218120000},"page":"107283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial"],"prefix":"10.1016","volume":"292","author":[{"given":"Joseph","family":"Rossano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Canter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Favatella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Puli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Javidialsaadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Dyme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Crevar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Mital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2025.107283_bib0001","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107283_bib0002","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.107283_bib0003","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jchf.2018.02.010","article-title":"Hypertrophic cardiomyopathy: clinical update","volume":"6","author":"Geske","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2025.107283_bib0004","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.jacc.2022.03.347","article-title":"Clinical features and natural history of preadolescent nonsyndromic hypertrophic cardiomyopathy","volume":"79","author":"Norrish","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107283_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.708679","article-title":"Childhood hypertrophic cardiomyopathy: a disease of the cardiac sarcomere","volume":"9","author":"Norrish","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ahj.2025.107283_bib0006","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamacardio.2018.0789","article-title":"Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events","volume":"3","author":"Maurizi","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2025.107283_bib0007","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa075463","article-title":"Shared genetic causes of cardiac hypertrophy in children and adults","volume":"358","author":"Morita","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.107283_bib0008","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/CIRCULATIONAHA.106.621185","article-title":"Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry","volume":"115","author":"Colan","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107283_bib0009","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa021715","article-title":"The incidence of pediatric cardiomyopathy in two regions of the United States","volume":"348","author":"Lipshultz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.107283_bib0010","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa021737","article-title":"The epidemiology of childhood cardiomyopathy in Australia","volume":"348","author":"Nugent","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.107283_bib0011","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/oxfordjournals.aje.a009291","article-title":"Epidemiology of idiopathic cardiomyopathies in children and adolescents. a nationwide study in Finland","volume":"146","author":"Arola","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ahj.2025.107283_bib0012","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107283_bib0013","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jacep.2022.07.012","article-title":"Temporal and global trends of the incidence of sudden cardiac death in hypertrophic cardiomyopathy","volume":"8","author":"Abdelfattah","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.ahj.2025.107283_bib0014","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2023.01.012","article-title":"Risk of sudden death in patients with RASopathy hypertrophic cardiomyopathy","volume":"81","author":"Lynch","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107283_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107283_bib0016","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/eurheartj\/ehz396","article-title":"Family screening for hypertrophic cardiomyopathy: is it time to change practice guidelines?","volume":"40","author":"Lafreniere-Roula","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.107283_bib0017","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.107283_bib0018","first-page":"1503","article-title":"Canadian Cardiovascular Society clinical practice update on contemporary management of the patient with hypertrophic cardiomyopathy","volume":"40","author":"Crean","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2025.107283_bib0019","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","article-title":"Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"18","author":"Ammirati","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2025.107283_bib0020","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1097\/JS9.0000000000000426","article-title":"Residual or recurrent obstruction after septal myectomy in young children and infants with hypertrophic cardiomyopathy: cohort study","volume":"109","author":"Dong","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.ahj.2025.107283_bib0021","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.athoracsur.2023.04.021","article-title":"Septal myectomy outcomes in children and adolescents with obstructive hypertrophic cardiomyopathy","volume":"116","author":"Griffeth","year":"2023","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ahj.2025.107283_bib0022","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.athoracsur.2012.08.011","article-title":"Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults","volume":"95","author":"Altarabsheh","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ahj.2025.107283_bib0023","series-title":"US prescribing information","year":"2023"},{"key":"10.1016\/j.ahj.2025.107283_bib0024","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.107283_bib0025","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107283_bib0026","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107283_bib0027","series-title":"European summary of product characteristics","year":"2025"},{"key":"10.1016\/j.ahj.2025.107283_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033968","article-title":"Exploring health-related quality of life in children with hypertrophic cardiomyopathy and relationship to physical activity","volume":"13","author":"Wagner","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2025.107283_bib0029","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107283_bib0030","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.107283_bib0031","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/psp4.13197","article-title":"Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration","volume":"13","author":"Chang","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ahj.2025.107283_bib0032","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1253\/circj.CJ-24-0501","article-title":"Phase 3 open-label study evaluating the efficacy and safety of mavacamten in Japanese adults with obstructive hypertrophic cardiomyopathy \u2013 the HORIZON-HCM study","volume":"89","author":"Kitaoka","year":"2024","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2025.107283_bib0033","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2025.107283_bib0034","unstructured":"Center for Disease Control National Center for Health Statistics. CDC growth charts. https:\/\/www.cdc.gov\/growthcharts\/cdc-charts.htm. 2024 (accessed December 3, 2024)."},{"key":"10.1016\/j.ahj.2025.107283_bib0035","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1124\/jpet.103.060137","article-title":"Developmental expression of human hepatic CYP2C9 and CYP2C19","volume":"308","author":"Koukouritaki","year":"2004","journal-title":"J Pharmacol Exp Ther"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325003370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325003370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:19:19Z","timestamp":1780906759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325003370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"alternative-id":["S0002870325003370"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.107283","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.107283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107283"}}